Serina Therapeutics Inc
(SER)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,879 | -11,284 | -4,822 | -11,207 | -8,455 |
| Depreciation Amortization | 49 | 33 | 17 | 539 | 475 |
| Accounts receivable | N/A | N/A | N/A | 65 | 51 |
| Accounts payable and accrued liabilities | 2,008 | 963 | 441 | N/A | -712 |
| Other Working Capital | 2,557 | 1,161 | 455 | -3,316 | -3,144 |
| Other Operating Activity | -657 | 1,055 | -413 | -3,218 | -763 |
| Operating Cash Flow | $-11,922 | $-8,072 | $-4,322 | $-17,137 | $-12,548 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -59 | -46 | N/A | -22 | -17 |
| Investing Cash Flow | $-59 | $-46 | $N/A | $-22 | $-17 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 4,913 | N/A | N/A | N/A | N/A |
| Debt Repayment | N/A | N/A | N/A | -168 | -167 |
| Common Stock Issued | 7,078 | 5,547 | 4,917 | 10,000 | 5,078 |
| Other Financing Activity | 4,940 | 4,940 | 0 | 3,380 | 3,270 |
| Financing Cash Flow | $16,931 | $10,487 | $4,917 | $13,212 | $8,181 |
| Exchange Rate Effect | -2 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 3,672 | 3,672 | 3,672 | 7,619 | 7,619 |
| End Cash Position | 8,620 | 6,041 | 4,267 | 3,672 | 3,235 |
| Net Cash Flow | $4,948 | $2,369 | $595 | $-3,947 | $-4,384 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,922 | -8,072 | -4,322 | -17,137 | -12,548 |
| Capital Expenditure | -59 | -46 | N/A | -22 | -17 |
| Free Cash Flow | -11,981 | -8,118 | -4,322 | -17,159 | -12,565 |